EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Adriana C Rodriguez, Zannel Blanchard, Kathryn A Maurer, Jason Gertz iD

Hormones and Cancer · 2019-06 · 10 (2-3) · 51-63

DOI: 10.1007/s12672-019-0358-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hormones and Cancer, online erschienen am 02.02.2019. Verfasst von Adriana C Rodriguez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Hauptthemen laut MEDLINE: Gene Expression Regulation, Neoplastic, Signal Transduction. Die Arbeit wurde bisher 278-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute, Congressionally Directed Medical Research Programs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen receptor α (ER) acts as an oncogenic signal. The major risk factors and some treatment options for endometrial cancer patients emphasize a key role for estrogen signaling in the disease. Despite the strong connections between estrogen signaling and endometrial cancer, important molecular aspects of ER function remain poorly understood; however, progress is being made in our understanding of estrogen signaling in endometrial cancer. Here, we discuss the evidence for the importance of estrogen signaling in endometrial cancer, details of the endometrial cancer-specific actions of ER, and open questions surrounding estrogen signaling in endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene Expression Regulation, NeoplasticSignal TransductionEndometrial NeoplasmsEstrogen Receptor alphaEstrogensFemaleHumansProgesteroneRisk FactorsSteroidsTranscription, Genetic

Stichwörter der Autor:innen

Endometrial cancerEstrogen receptor alphaEstrogen signalingGene regulationProgesterone signaling

Substanzen

ESR1 protein, humanEstrogen Receptor alphaEstrogensSteroidsProgesterone

Autor:innen und Institutionen

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. jay.gertz@hci.utah.edu.
  • Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA. jay.gertz@hci.utah.edu.

ORCID-Profile: Jason Gertz

Förderung

  • NHGRI NIH HHS
  • National Human Genome Research Institute
  • Congressionally Directed Medical Research Programs

Zitieren

APA

Rodriguez, A. C., Blanchard, Z., Maurer, K. A., & Gertz, J. (2019). Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions. Hormones and Cancer, 10(2-3), 51-63. https://doi.org/10.1007/s12672-019-0358-9

Vancouver

Rodriguez AC, Blanchard Z, Maurer KA, Gertz J. Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions. Hormones and Cancer. 2019;10(2-3):51-63. doi:10.1007/s12672-019-0358-9

BibTeX
@article{Rodriguez2019,
  author = {Rodriguez, Adriana C and Blanchard, Zannel and Maurer, Kathryn A and Gertz, Jason},
  title = {Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions},
  journal = {Hormones and Cancer},
  year = {2019},
  volume = {10},
  number = {2-3},
  pages = {51--63},
  doi = {10.1007/s12672-019-0358-9}
}
Kostenlos starten →